Middle East Pharmaceutical Industries Company SJSC
SAU:4016
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
O
|
Ortivus AB
STO:ORTI B
|
SE |
|
First Solar Inc
NASDAQ:FSLR
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (19.9), the stock would be worth ﷼126.74 (5% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 19.1 | ﷼121.2 |
0%
|
| 3-Year Average | 19.9 | ﷼126.74 |
+5%
|
| 5-Year Average | 19.9 | ﷼126.74 |
+5%
|
| Industry Average | 19.2 | ﷼121.8 |
+0%
|
| Country Average | 14.5 | ﷼91.92 |
-24%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| SA |
M
|
Middle East Pharmaceutical Industries Company SJSC
SAU:4016
|
2.4B SAR | 19.1 | 25 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
867B USD | 27.4 | 40.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
555.4B USD | 16.7 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.9 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 15.6 | 28 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 12.1 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
283.6B USD | 9.5 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 386.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 8.4 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.6B USD | 7.6 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.8B USD | 7.2 | 16.8 |
Market Distribution
| Min | 1.5 |
| 30th Percentile | 11.1 |
| Median | 14.5 |
| 70th Percentile | 20.1 |
| Max | 24 279.8 |
Other Multiples
Middle East Pharmaceutical Industries Company SJSC
Glance View
Middle East Pharmaceutical Industries Company SJSC is a SA-based company operating in Pharmaceuticals industry. The company is headquartered in Riyadh, Riyadh and currently employs 335 full-time employees. The company went IPO on 2024-02-27. Middle East Pharmaceutical Industries Company SJSC is a Saudi Arabia-based pharmaceutical company. The firm develops, manufactures, markets, and distributes a wide range of generic medicines and pharmaceuticals. The Company’s activity is the manufacture of disinfectants and sterilizers for medical devices and products, the manufacture of disinfectants and sterilizers for non-medical use, the manufacture of cosmetics, and the manufacture of pharmaceutical preparations for human use.
